An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone.

The OSCAR study was a multicenter, open-label RCT carried out in Japanese elderly hypertensive patients. Patients were randomized to angiotensin II receptor blocker (ARB) dose up-titration versus an ARB plus calcium channel blocker combination.
In the pre-specified subgroup of patients with CKD, more primary events (a composite of cardiovascular events and noncardiovascular death) occurred in the high-dose ARB group than in the combination group.
:

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis
The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis

Source: Nephrology Now - January 28, 2013 Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Chronic Kidney Disease Hypertension Source Type: research